Investment Rating - The report maintains a "Recommended" investment rating for the company [1][2]. Core Views - The company's overall revenue for 2023 was 8.54 billion yuan, a decrease of 44.82% year-on-year, primarily due to reduced testing demand related to public health events. However, routine medical testing revenue showed a recovery with a 15.35% year-on-year increase, reaching 7.73 billion yuan [2][3]. - The company is accelerating its digital transformation, achieving significant results with its "Medical Testing 4.0" initiative, which includes the establishment of specialized disease databases and the implementation of automated and intelligent systems to enhance laboratory efficiency [2][3]. - Despite a short-term performance pressure in Q1 2024, with revenue of 1.84 billion yuan (down 13.05% year-on-year) and a net loss of 19 million yuan, the long-term growth momentum remains intact. The company plans to enhance its core capabilities through cost management, new product development, and digital transformation [2][3]. Financial Summary - For 2023, the company reported total revenue of 8.54 billion yuan, with a year-on-year growth rate of -44.8%. The net profit attributable to shareholders was 643 million yuan, down 76.6% year-on-year [3]. - The forecast for net profit attributable to shareholders for 2024, 2025, and 2026 is adjusted to 1.11 billion yuan, 1.34 billion yuan, and 1.61 billion yuan, respectively, with corresponding P/E ratios of 16, 13, and 11 times [2][3]. - The company's total market value is approximately 17.86 billion yuan, with a current share price of 38.10 yuan [6].

Summary of Conference Call Company/Industry Involved - The document pertains to a conference call related to a company's annual report and its first quarter 2024 report. Core Points and Arguments - The conference call was initiated to discuss the annual report and the first quarter 2024 results, indicating a focus on financial performance and strategic outlook for the upcoming period [1]. Other Important but Possibly Overlooked Content - The call emphasized the importance of institutional investor engagement, suggesting that the company values feedback and interaction with its investors [1].

Investment Rating - The investment rating for the company is not explicitly stated in the provided report, but it can be inferred that the company is viewed positively based on the growth projections and strategic initiatives discussed. Core Insights - The company reported a significant decline in revenue and net profit for 2023, with total revenue of 8.54 billion yuan, down 44.82% year-over-year, and a net profit of 0.643 billion yuan, down 76.64% year-over-year. However, the conventional medical diagnostic services segment showed a recovery with a revenue increase of 15.35% year-over-year, reaching 7.726 billion yuan in 2023 [1][2]. - The company is focusing on high-quality development in conventional medical diagnostic services, with a notable increase in revenue from core disease lines, including a 30.32% growth in neurological and psychiatric disease diagnostics and a 49.74% growth in infectious disease diagnostics [1][2]. - The company is accelerating its digital transformation to enhance profitability, implementing AI technologies to improve operational efficiency and customer experience. The gross profit margin for 2023 was reported at 36.48% [1][2]. Financial Performance Summary - In 2023, the company achieved total revenue of 8.54 billion yuan, with a year-over-year growth rate of -44.8%. The projected revenues for 2024, 2025, and 2026 are 9.713 billion yuan, 11.364 billion yuan, and 13.307 billion yuan, respectively, with expected growth rates of 13.7%, 17.0%, and 17.1% [2][3]. - The net profit attributable to the parent company for 2023 was 0.643 billion yuan, a decrease of 76.6% year-over-year. The forecasted net profits for the next three years are 0.676 billion yuan, 0.966 billion yuan, and 1.329 billion yuan, with growth rates of 5.1%, 42.9%, and 37.5% [2][3]. - The company's gross margin for 2023 was 36.5%, down from 43.1% in 2022, with expectations for gradual recovery in profitability as cost reduction measures take effect [1][2].

广州金域医学检验集团股份有限公司 2023 年度独立董事述职报告 本人作为广州金域医学检验集团股份有限公司（以下简称"公司"）第三届 董事会独立董事，严格按照《公司法》、《上市公司独立董事管理办法》、《公 司章程》、《独立董事工作制度》等规定，在 2023 年度工作中，忠实履行独立 董事的职责，积极参加股东大会、董事会、各专门委员会等会议，认真审议各项 议案并对相关事项发表意见，切实维护公司和全体股东特别是中小股东的合法权 益。现就 2023 年度履职情况汇报如下： 一、独立董事基本情况 余玉苗, 男，出生于 1965 年，中国国籍，无境外永久居留权。博士研究生 学历。1986 年毕业于武汉大学，获得经济学学士；1997 年毕业于武汉大学，获 得经济学博士。1989 年至 1996 年，任武汉大学经济学院会计与审计系讲师；1996 年至 2001 年，任武汉大学经济学院会计与审计系副教授、系副主任；2001 年至 2013 年，任武汉大学经济与管理学院会计系教授、博士生导师、系副主任；曾 任美国加州大学厄湾分校和香港科技大学访问学者；2013 年至今，任武汉大学 经济与管理学院会计系教授、博士生导师。2017 ...

金域医学管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业务办理》的相关规定编制了后附的 2023 年度非经营性资金 占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、合法和完整是金域医学管理层 的责任。我们将汇总表所载信息与我们审计金域医学公司 2023 年度 财务报表时所审核的会计资料及已审计财务报表中披露的相关内容 进行了核对，没有发现在重大方面存在不一致的情况。 专项报告第1页 广州金域医学检验集团股份有限公司 关联方占用资金专项审计说明 2023 年度 关于广州金域医学检验集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZA11790 号 广州金域医学检验集团股份有限公司全体股东： 我们审计了广州金域医学检验集团股份有限公司(以下简称"金 域医学")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母 公司资产负债表、2023 年度合并及母公司利润表、 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 证券代码：603882 证券简称：金域医学 公告编号：2024-037 广州金域医学检验集团股份有限公司 关于计提资产减值准备的公告 | | 按信用风险特征组合计提坏账准备的计提方法 | | | --- | --- | --- | | 组别 | 内容 | 计提方法 | | 组合一 | 合并范围内关联方应收款项及保证金 | 不计提 | | 组合二 | 除对单项金额重大并已单项计提或单项金额虽 | 账龄分析法 | | | 不重大但已单项计提坏账准备的应收账款和组 | | | | 合一之外的应收款项，公司根据以前年度与之 | | | | 相同或类似的、按账龄段划分的具有类似信用 | | | | 风险特征的应收款项组合 | | 为了客观、公允地反映广州金域医学检验集团股份有限公司（以下简称"公 司"）的财务状况以及经营成果，根据《企业会计准则》相关规定和公司会计政 策，公司对合并报表范围内各项资产进行了减值测试，相应计提资产减值准备。 详见下表： 单位：人民 ...

广州金域医学检验集团股份有限公司 对会计师事务所 2023 年度履职情况评估报告 广州金域医学检验集团股份有限公司(以下简称"公司")聘请立信会计师 事务所(特殊普通合伙)(以下简称"立信")为公司 2023年度审计机构。根据 《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司治理准则》、 《国有企业、上市公司选聘会计师事务所管理办法》等相关法律法规以及《公司 章程》等相关规章制度的要求,公司对立信 2023年度履职情况进行评估。具体 情况如下: 一、资质条件 立信会计师事务所(特殊普通合伙)由我国会计泰斗潘序伦博士于 1927年 在上海创建,1986年复办,2010年成为全国首家完成改制的特殊普通合伙制会 计师事务所,注册地址为上海市。立信是国际会计网络 BDO 的成员所,长期从 事证券服务业务,新证券法实施前具有证券、期货业务许可证,具有 H 股审计 资格,并已向美国公众公司会计监督委员会(PCAOB)注册登记。 截至 2023 年末,立信拥有合伙人 278 名、注册会计师 2,533 名、从业人员 总数 10.730 名,签署过证券服务业务审计报告的注册会计师 693 名。 二、执业记录 1 ...

广州金域医学检验集团股份有限公司 网址：www.kingmed.com.cn 报告出版环境 纸张：本报告采用环保纸张印刷。 报告编制说明 | 本报告是广州金域医学检验集团股份有限公 | | --- | | 的首份可持续发展报告。前一份报告于202 | | 的原则,详细披露了金域医学2023年度在环 | 报告范围 | | | 编制依据 全球报告倡议组织（GRI）《可持续发展报告编写标准》（GRI Standards） 上海证券交易所《上海证券交易所上市公司自律监管指引第1号——规范运作》和《上海证券交 易所上市公司自律监管指引第14号——可持续发展报告（试行）》 中国社科院《中国企业社会责任报告指南（CASS-ESG 5.0）》 报告说明 | 金域医学保证本报告内容不存在任何虚假记载和误导性陈述，所载数据的收集流程、计算方法 | | --- | | 等均与公司年度报告披露的相同指标保持一致。本报告中所涉及货币金额以人民币为计量币 | | 种，特殊说明除外。 | | 为便于表述和阅读，在报告中"广州金域医学检验集团股份有限公司"也以"金域医学""金 | "基金会"表示。 获取方式 本报告包括纸质和电子版本，您可登 ...

证券代码：603882 证券简称：金域医学 公告编号：2024-036 广州金域医学检验集团股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2024 年 5 月 20 日 14 点 30 分 召开地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 20 日 至 2024 年 5 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东大会召开日期：2024年5月20日 本次股东大会采用的网络投票系统：上海 ...

Company Structure and Subsidiaries - Guangzhou Kingmed Diagnostics Group Co., Ltd. is the main entity referred to as "the company" in the report[11] - The company has a wide network of subsidiaries across various regions in China, including Guangzhou, Shanghai, Beijing, and others[11][12] - Key subsidiaries include Guangzhou Kingmed Judicial Expertise Technology Co., Ltd. and Guangzhou Kingmed Medical Examination Center Co., Ltd.[11] - The company operates in multiple provinces and cities, such as Fujian, Guizhou, Hainan, and Zhejiang[11] - Subsidiaries like Guangzhou Kingmed Logistics Co., Ltd. and Guangzhou Kingmed Health Management Co., Ltd. support the company's operations[11] - The company has expanded its presence to international markets, including Hong Kong[11] - Subsidiaries such as Guangzhou Kingmed Future Biotechnology Co., Ltd. and Guangzhou Kingmed Jian Shi Innovation Research Institute Co., Ltd. focus on innovation and research[12] - The company has established a strong presence in less developed regions like Xinjiang, Ningxia, and Qinghai[12] - Subsidiaries like Guangzhou Kingmed Medical Laboratory Co., Ltd. and Guangzhou Kingmed Medical Laboratory Technology Co., Ltd. are key to the company's diagnostic services[11][12] - The company's subsidiaries are involved in various aspects of medical testing, including microbiology, immunology, and pathology[12] Financial Performance and Costs - Third-party medical diagnostic services' delivery costs decreased by 31.29% to 431.58 million yuan, accounting for 8.66% of total costs[53] - Other costs for third-party medical diagnostic services dropped by 50.28% to 1.15 billion yuan, representing 23.17% of total costs[53] - Total operating costs decreased by 38.37% to 5.42 billion yuan, with medical diagnostic services accounting for 91.83% of total costs[53] - R&D expenses decreased by 26.16% to 467.14 million yuan, accounting for 5.47% of total revenue[57][58] - Operating cash flow decreased by 36.81% to 1.23 billion yuan, while investment cash flow improved by 25.21% to -634.53 million yuan[61] - Inventory decreased by 38.75% to 248.21 million yuan, accounting for 2.11% of total assets[62] - The company invested in Zhenmai Biotechnology, increasing other non-current financial assets by 96.24% to 292.58 million yuan[62] - Overseas assets totaled 614.46 million yuan, accounting for 5.22% of total assets[63] - The company acquired a 12% stake in Tianhai Xinyuan Biotechnology, increasing its shareholding to 60% and resulting in a 59.75% increase in goodwill to 52.21 million yuan[54][62] Corporate Governance and Commitments - The company's controlling shareholder and actual controller, Liang Yaoming, along with his concerted parties, have committed to avoiding any business activities that directly or indirectly compete with the company's main business or products[154] - The company has pledged to minimize and avoid related-party transactions, ensuring that any unavoidable transactions are conducted at fair market prices and in compliance with legal and regulatory requirements[154] - Liang Yaoming has committed to not transferring the newly issued shares obtained from the private placement for 36 months from the date of the placement's completion[155] - The company's directors and senior management have committed to not engaging in any activities that would harm the company's interests, including unfair transactions or misuse of company assets[155] - The company's controlling shareholder, Liang Yaoming, has promised not to interfere with the company's management activities or encroach on the company's interests[156] - Incentive objects under the 2019 equity incentive plan have committed to returning all benefits obtained from the plan if the company's information disclosure documents are found to contain false statements or major omissions[156] Research and Development - The company has 1,397 R&D personnel, representing 12.06% of total employees, with 31 holding PhD degrees and 295 holding master's degrees[59]